<DOC>
	<DOC>NCT00375596</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of a new allergy medication</brief_summary>
	<brief_title>A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis</brief_title>
	<detailed_description>Study withdrawn prior to determining study details</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Vasoconstrictor Agents</mesh_term>
	<criteria>Be at least 6 years of age, of any race, or either gender. Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months. Have a calculated bestcorrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart. Positive bilateral CAC reaction at Visit 1 &amp; 2. Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components. Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slitlamp exam of any visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>